Geert Cauwenbergh

Fondateur chez Phases 123 LLC

Profil

Geert Cauwenbergh is the founder of Aramis LLC (founded in 2008), Barrier Therapeutics, Inc. (founded in 2001), and Phases 123 LLC (founded in 2008).
He held the title of Chairman & Chief Executive Officer at Barrier Therapeutics, Inc. Dr. Cauwenbergh currently holds the position of Executive Chairman at Expressive Constructs, Inc. and Director at Cutanea Life Sciences, Inc., Alto Pharmaceuticals Ltd., and Legacy Healthcare (Switzerland) SA. Dr. Cauwenbergh previously held the position of Chairman & Chief Executive Officer at RHEI Pharmaceuticals, Inc. and Chief Executive Officer at RHEI Pharmaceuticals HK Ltd. He also served as Chairman-Trustees Board at BioNJ, Inc., Director & Vice President-Product Development at Johnson & Johnson Holdco (NA), Inc., Independent Director at Avecho Biotechnology Ltd., Independent Director at Ablynx NV, Director at Ogeda SA, Director at CalEthos, Inc., Director at DARA BioSciences, Inc., Independent Director at Moberg Pharma AB, and Independent Director at Phio Pharmaceuticals Corp.
Dr. Cauwenbergh was also a Managing Director at the Center for Medical Innovation.
He held the position of Vice President-Research & Development at Johnson & Johnson from 1994 to 2002 and Vice President-Technology at Johnson & Johnson Consumer & Personal Care.
Dr. Cauwenbergh obtained a doctorate degree from Université Catholique de Louvain.

Postes actifs de Geert Cauwenbergh

Sociétés	Poste	Début
Expressive Constructs, Inc.	Président	01/02/2011
Phases 123 LLC	Fondateur	25/04/2011
Cutanea Life Sciences, Inc.	Directeur/Membre du Conseil	01/09/2011
Alto Pharmaceuticals Ltd.	Directeur/Membre du Conseil	-
Legacy Healthcare (Switzerland) SA	Directeur/Membre du Conseil	-

Anciens postes connus de Geert Cauwenbergh

Sociétés	Poste	Fin
PHIO PHARMACEUTICALS CORP.	Directeur Général	29/09/2022
MOBERG PHARMA AB	Directeur/Membre du Conseil	15/05/2019
AVECHO BIOTECHNOLOGY LIMITED	Directeur/Membre du Conseil	30/05/2017
ABLYNX	Directeur/Membre du Conseil	25/04/2013
░░░░ ░░░░░░░░░░░░░░░░ ░░░░	░░░░░░░░░ ░░░░░░░░░	░░░░░░░░░░